Dr.Reddy's Laboratories Ltd (ADR) (RDY) is Downgraded by HSBC Securities to Reduce

Dr.Reddy's Laboratories Ltd (ADR) (RDY) was Downgraded by HSBC Securities to ” Reduce”. Earlier the firm had a rating of “Hold ” on the company shares. HSBC Securities advised their investors in a research report released on Jul 27, 2016.

Dr.Reddy's Laboratories Ltd (ADR) closed down -0.21 points or -0.48% at $43.61 with 5,53,122 shares getting traded on Thursday. Post opening the session at $43.85, the shares hit an intraday low of $43.19 and an intraday high of $44.05 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

Dr. Reddy’s Laboratories Limited is an integrated global pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics Pharmaceutical Services and Active Ingredients (PSAI) and Proprietary Products. Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company’s business of manufacturing and marketing active pharmaceutical ingredients and intermediates also known as API or bulk drugs. Proprietary Products segment consists of its differentiated formulations business its new chemical entities (NCEs) business and its dermatology focused specialty business operated through Promius Pharma.

Dr.Reddy's Laboratories Ltd (ADR)

Leave a Reply

Dr.Reddy's Laboratories Ltd (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Dr.Reddy's Laboratories Ltd (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.